Regeneron and Sanofi announce positive Phase 3 trial results for Dupixent in chronic spontaneous urticaria, showing significant itch and hive reductions.
Regeneron Pharmaceuticals and Sanofi announced positive results from a Phase 3 trial of Dupixent (dupilumab) for chronic spontaneous urticaria (CSU), showing significant reductions in itch and hives. In the study, 30% of treated patients experienced complete response compared to 18% on placebo. The companies plan to submit these results to the FDA by year-end 2024, aiming for Dupixent to be the first targeted therapy for CSU in a decade.
September 11, 2024
15 Articles